Table 4.
Description of hypercoagulopathic complications (confirmed DVT and catheter thrombosis (≥3 episodes), stroke, and use of therapeutic anticoagulation)
| Patient number | DVT | DVT location | Clotted central venous catheters | Confirmed stroke | Therapeutic anticoagulation | Anticoagulation use (days) | HD | Comorbidities |
| 1 | – | – | Y | – | Y | 4 | Y | MG |
| 2 | – | – | – | – | – | – | – | HLD, HTN |
| 3 | – | – | Y | – | Y | 24 | – | HTN, DM |
| 4 | – | – | – | – | Y | 6 | – | None |
| 5 | – | – | – | – | – | – | – | HTN, TIA |
| 6 | – | – | – | – | – | – | Y | HTN |
| 7 | Y | Brachial vein | – | Y | Y | 6 | – | None |
| 8 | – | – | – | – | Y | 2 | – | CP |
| 9 | – | – | – | – | Y | 3 | – | DA |
| 10 | – | – | – | – | – | – | – | CILI |
| 11 | Y | Internal jugular | – | – | Y | 7 | – | HTN, EtOH |
| 12 | – | – | – | – | Y | 23 | Y | HLD, PVD, SZ |
| 13 | – | – | – | – | Y | 3 | Y | HTN, CHF |
| 14 | – | – | – | – | – | – | – | HTN |
| 15 | – | – | – | – | Y | 9 | Y | HTN, DM, MG |
| 16 | – | – | – | – | – | – | – | CILI, EtOH |
| 17 | – | – | – | Y | Y | 14 | – | ARF, HTN, DM |
| 18 | – | – | – | – | Y | 15 | – | HTN, DM, TIA |
| 19 | – | – | – | – | Y | 11 | Y | HTN, DM |
| 20 | – | – | – | – | Y | 6 | – | HLD, CHF, HTN, COPD, CAD |
| 21 | – | – | – | Y | Y | 2 | Y | HLD, HTN, DM |
CAD, coronary artery disease; CHF, congestive heart failure; CILI, cirrhosis of the liver; COPD, chronic obstructive pulmonary disease; CP, cerebral palsy; DA, drug abuse; DM, diabetes; DVT, deep vein thrombosis; EtOH, alcohol use; HD, hemodialysis; HLD, hyperlipidemia; HTN, hypertension; MG, myasthenia gravis; PVD, peripheral vascular disease; SZ, seizure; TIA, transient ischemic attack; Y, yes.